Pathological Myopia Clinical Trial
Official title:
Genomewide Screening of Pathological Myopia
The purpose of this study is to evaluate the possible candidate gene of pathological myopia
High myopia (pathological myopia) is caused by excessive axial elongation that primarily
involves the ora-equatorial area and the posterior pole. Peripheral fundus changes and
posterior staphyloma formation are ophthalmoscopic evidences of this process. Pathological
myopia often accompanied by glaucoma, cataracts, macular degeneration, and retinal
detachment, leading to blindness when the damage to the retina is extremely severe.
Population and family studies in Chinese have provided evidence for a genetic component to
pathologic myopia. Children of myopic parents are more likely to have myopia than are
children of nonmyopic parents. The ocular components (axial length, anterior chamber depth,
and corneal curvature) and refractive errors of MZ twins are more closely aligned than are
those of DZ twins.
Therefore, it is possible to search a potential candidate gene for myopia through the
genomic study of pathological myopia.
;
Observational Model: Case Control
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01217944 -
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
|
Phase 3 | |
| Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT00407719 -
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
|
Phase 1 | |
| Recruiting |
NCT03128463 -
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
|
N/A |